

Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.



October 5, 2023

Company name: TMS Co., Ltd.
Name of representative: Takuro Wakabayashi, Chief Executive Officer
(Securities code: 4891; Growth Market)

Notice Concerning the Patent for which TMS is granted license to use

TMS Co., Ltd. (the “Company”) announces today that the patent has been granted in Japan with regard to the patent application that the Company had filed jointly with Showa University on March 23, 2018 and assigned its share belonging to the Company to Biogen MA, Inc. (“Biogen”) upon Biogen’s exercise of the option rights on May 11, 2021 based on the Option Agreement dated as of June 5, 2018.

Under the terms of the Option Agreement, the Company is granted license by Biogen to use Biogen's share of the patent. The patent is about a use invention related to a new treatment for acute kidney injury using TMS-008, which the Company is currently developing.

Patent Summary

Title of invention : Drug and method for treating or preventing kidney disease using the drug
International Publication Number : WO2019/181388
Patent number in Japan : Patent No. 7356113
Registration date : October 4, 2023
Applicant : Biogen, Showa University

This matter will not have any impact on the financial results for the fiscal year ending on February 29, 2024.

About TMS Co., Ltd.

TMS is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of serious diseases to address medical unmet needs. The Company’s pipeline consists of a family of small compounds called SMTPs (Stachybotrys microspora triprenyl phenols) derived from a fungus. The lead pipeline compound, TMS-007, is indicated for the treatment of acute ischemic stroke. It demonstrated efficacy and safety in the completed Phase 2 study and was acquired by Biogen in 2021. Another SMTP compound, TMS-008, is under development for acute kidney injury and other potential indications. In addition, the Company is exploring new pipeline products by focusing on early-stage seeds from academic institutions in Japan, with the intention to build a bridge between academic discoveries and the global pharmaceutical market. For more information about TMS, please visit <https://www.tms-japan.co.jp/>.

Investor and Media Contact:

ir@tms-japan.co.jp

End